Le Lézard
Classified in: Science and technology, Business
Subjects: FNC, OFR

Kneat Announces $11 Million Overnight Marketed Equity Financing


/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

HALIFAX, Feb 27, 2020 /CNW/ - kneat.com, inc. (TSXV: KSI) ("Kneat") is pleased to announce that, in connection with its previously announced overnight marketed offering, it has entered into an underwriting agreement with a syndicate of underwriters co-led by Cormark Securities Inc. and Canaccord Genuity Corp., and including Echelon Wealth Partners Inc. and Mackie Research Capital Corporation (collectively, the "Underwriters"), to sell 5,238,500 Common Shares of the Company ("Securities") at a price of $2.10 per Security for aggregate gross proceeds of $11,000,850 (the "Offering").

Kneat will shortly file an amended and restated preliminary short form prospectus with the securities commissions in all of the provinces of Canada, other than Québec, to reflect the terms of the Offering.

Kneat has granted the Underwriters an option (the "Over-Allotment Option") to purchase up to an additional 785,775 of Securities on the same terms as the Offering for additional gross proceeds of $1,650,128, exercisable at any time up to 30 days following the closing of the Offering, for market stabilization purposes and to cover over-allotments, if any.

In addition, the Company intends to complete a concurrent non-brokered private placement of approximately $2.5 million to certain shareholders (the "Concurrent Private Placement"). The Securities issuable pursuant to the Concurrent Private Placement will be on the same terms as those issuable pursuant to the Offering, except that they will be subject to a statutory four month hold period in accordance with applicable securities laws.

Closing of the Offering and the Concurrent Private Placement is expected to occur on or about March 12, 2020 and is subject to regulatory approval, including that of the TSX Venture Exchange.

The Company intends to use the net proceeds of the Offering and Concurrent Private Placement for growth initiatives, working capital and general corporate purposes.

The Securities to be issued under the Offering will be offered by way of a short form prospectus in each of the provinces of Canada, other than Québec, and may be offered in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws, and certain other jurisdictions outside of Canada and the United States.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.

About Kneat

Kneat, a Canadian company with operational headquarters in Limerick, Ireland, develops and markets the next generation Kneat Gx software platform. Multiple business work processes can be configured on the platform from equipment to computer system validation, through to quality document management. Kneat's software allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes globally. Customer case studies report productivity improvements in excess of 100% and a higher data integrity and compliance standard. For more information visit www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented herein constitutes "forward-looking information" within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, information relating to the proposed Offering, the Concurrent Private Placement and the use of proceeds. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties. Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investors' own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE kneat.com, inc.


These press releases may also interest you

at 07:10
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent...

at 07:10
IMV Inc. , a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company's business and clinical operations amid...

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....

at 07:05
Generation Bio and Vir Biotechnology today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's current or future human monoclonal...



News published on 27 february 2020 at 09:39 and distributed by: